Raras
Buscar doenças, sintomas, genes...
Doença de Charcot-Marie-Tooth intermédia autossómicadominante
ORPHA:90114CID-11 · 8C20.2DOENÇA RARA

Forma autossômica dominante da doença intermediária de Charcot-Marie-Tooth.

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

Forma autossômica dominante da doença intermediária de Charcot-Marie-Tooth.

Publicações científicas
4 artigos
Último publicado: 2019 Sep 10

Escala de raridade

CLASSIFICAÇÃO ORPHANET · BRASIL 2024
Unknown
Ultra-rara
<1/50k
Muito rara
1/20k
Rara
1/10k
Pouco freq.
1/5k
Incomum
1/2k
Prevalência
0.0
Worldwide
Início
Adolescent
+ adult, childhood
🏥
SUS: Sem cobertura SUSScore: 0%
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

💪
Músculos
13 sintomas
🧠
Neurológico
7 sintomas
🦴
Ossos e articulações
6 sintomas
👂
Ouvidos
3 sintomas
👁️
Olhos
3 sintomas
🫘
Rins
2 sintomas

+ 33 sintomas em outras categorias

Características mais comuns

Proteinúria
Aumento da concentração de proteína no LCR
Deficiência auditiva
Morfologia anormal da pupila
Velocidade de condução nervosa diminuída
Fraqueza muscular
69sintomas
Sem dados (69)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 69 características clínicas mais associadas, ordenadas por frequência.

ProteinúriaProteinuria
Aumento da concentração de proteína no LCRIncreased CSF protein concentration
Deficiência auditivaHearing impairment
Morfologia anormal da pupilaAbnormal pupil morphology
Velocidade de condução nervosa diminuídaDecreased nerve conduction velocity

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa7desde 2019
Total histórico4PubMed
Últimos 10 anos3publicações
Pico20193 papers
Linha do tempo
20202019Hoje · 2026
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

6 genes identificados com associação a esta condição. Padrão de herança: Autosomal dominant.

INF2Inverted formin-2Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Severs actin filaments and accelerates their polymerization and depolymerization

LOCALIZAÇÃO

Cytoplasm, perinuclear region

MECANISMO DE DOENÇA

Focal segmental glomerulosclerosis 5

A renal pathology defined by the presence of segmental sclerosis in glomeruli and resulting in proteinuria, reduced glomerular filtration rate and progressive decline in renal function. Renal insufficiency often progresses to end-stage renal disease, a highly morbid state requiring either dialysis therapy or kidney transplantation.

EXPRESSÃO TECIDUAL(Ubíquo)
Nervo tibial
204.3 TPM
Artéria tibial
83.2 TPM
Artéria coronária
78.6 TPM
Aorta
69.0 TPM
Brain Spinal cord cervical c-1
68.8 TPM
OUTRAS DOENÇAS (3)
Charcot-Marie-Tooth disease dominant intermediate Efocal segmental glomerulosclerosis 5familial idiopathic steroid-resistant nephrotic syndrome
HGNC:23791UniProt:Q27J81
DNM2Dynamin-2Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Catalyzes the hydrolysis of GTP and utilizes this energy to mediate vesicle scission at plasma membrane during endocytosis and filament remodeling at many actin structures during organization of the actin cytoskeleton (PubMed:15731758, PubMed:19605363, PubMed:19623537, PubMed:33713620, PubMed:34744632). Plays an important role in vesicular trafficking processes, namely clathrin-mediated endocytosis (CME), exocytic and clathrin-coated vesicle from the trans-Golgi network, and PDGF stimulated macr

LOCALIZAÇÃO

Cytoplasm, cytoskeletonCytoplasmic vesicle, clathrin-coated vesicleCell projection, uropodiumEndosomeCytoplasm, cytoskeleton, microtubule organizing center, centrosomeCytoplasm, cytoskeleton, microtubule organizing center, centrosome, centrioleRecycling endosomeCell projection, phagocytic cupCytoplasmic vesicle, phagosome membraneCell projection, podosomeCytoplasmCell junctionPostsynaptic densitySynapse, synaptosomeMidbodyMembrane, clathrin-coated pit

VIAS BIOLÓGICAS (1)
NOSTRIN mediated eNOS trafficking
MECANISMO DE DOENÇA

Myopathy, centronuclear, 1

A congenital muscle disorder characterized by progressive muscular weakness and wasting involving mainly limb girdle, trunk, and neck muscles. It may also affect distal muscles. Weakness may be present during childhood or adolescence or may not become evident until the third decade of life. Ptosis is a frequent clinical feature. The most prominent histopathologic features include high frequency of centrally located nuclei in muscle fibers not secondary to regeneration, radial arrangement of sarcoplasmic strands around the central nuclei, and predominance and hypotrophy of type 1 fibers.

EXPRESSÃO TECIDUAL(Ubíquo)
Pulmão
107.7 TPM
Skin Sun Exposed Lower leg
97.2 TPM
Sangue
94.9 TPM
Intestino delgado
92.3 TPM
Baço
85.9 TPM
OUTRAS DOENÇAS (5)
fetal akinesia-cerebral and retinal hemorrhage syndromeautosomal dominant centronuclear myopathyCharcot-Marie-Tooth disease dominant intermediate Bcentronuclear myopathy
HGNC:2974UniProt:P50570
GBF1Golgi-specific brefeldin A-resistance guanine nucleotide exchange factor 1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Guanine-nucleotide exchange factor (GEF) for members of the Arf family of small GTPases involved in trafficking in the early secretory pathway; its GEF activity initiates the coating of nascent vesicles via the localized generation of activated ARFs through replacement of GDP with GTP. Recruitment to cis-Golgi membranes requires membrane association of Arf-GDP and can be regulated by ARF1, ARF3, ARF4 and ARF5. Involved in the recruitment of the COPI coat complex to the endoplasmic reticulum exit

LOCALIZAÇÃO

Golgi apparatus, cis-Golgi networkEndoplasmic reticulum-Golgi intermediate compartmentGolgi apparatus, trans-Golgi networkGolgi apparatusCytoplasmLipid dropletMembrane

VIAS BIOLÓGICAS (3)
COPI-mediated anterograde transportDengue Virus-Host InteractionsCOPI-dependent Golgi-to-ER retrograde traffic
MECANISMO DE DOENÇA

Charcot-Marie-Tooth disease, axonal, type 2GG

An axonal form of Charcot-Marie-Tooth disease, a disorder of the peripheral nervous system, characterized by progressive weakness and atrophy, initially of the peroneal muscles and later of the distal muscles of the arms. Charcot-Marie-Tooth disease is classified in two main groups on the basis of electrophysiologic properties and histopathology: primary peripheral demyelinating neuropathies (designated CMT1 when they are dominantly inherited) and primary peripheral axonal neuropathies (CMT2). Neuropathies of the CMT2 group are characterized by signs of axonal degeneration in the absence of obvious myelin alterations, normal or slightly reduced nerve conduction velocities, and progressive distal muscle weakness and atrophy. CMT2GG is an autosomal dominant form characterized by slowly progressive distal muscle weakness and atrophy primarily affecting the lower limbs and causing difficulty walking. Some individuals may also have involvement of the hands.

EXPRESSÃO TECIDUAL(Ubíquo)
Pituitária
70.4 TPM
Cerebelo
66.7 TPM
Tireoide
66.5 TPM
Útero
60.7 TPM
Cervix Endocervix
58.4 TPM
OUTRAS DOENÇAS (1)
Charcot-Marie-Tooth Disease, axonal, type 2GG
HGNC:HGNC:4181UniProt:Q92538
MPZMyelin protein P0Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Is an adhesion molecule necessary for normal myelination in the peripheral nervous system. It mediates adhesion between adjacent myelin wraps and ultimately drives myelin compaction

LOCALIZAÇÃO

Cell membraneMyelin membrane

VIAS BIOLÓGICAS (1)
EGR2 and SOX10-mediated initiation of Schwann cell myelination
MECANISMO DE DOENÇA

Charcot-Marie-Tooth disease, demyelinating, type 1B

A dominant demyelinating form of Charcot-Marie-Tooth disease, a disorder of the peripheral nervous system, characterized by progressive weakness and atrophy, initially of the peroneal muscles and later of the distal muscles of the arms. Charcot-Marie-Tooth disease is classified in two main groups on the basis of electrophysiologic properties and histopathology: primary peripheral demyelinating neuropathies (designated CMT1 when they are dominantly inherited) and primary peripheral axonal neuropathies (CMT2). Demyelinating neuropathies are characterized by severely reduced nerve conduction velocities (less than 38 m/sec), segmental demyelination and remyelination with onion bulb formations on nerve biopsy, slowly progressive distal muscle atrophy and weakness, absent deep tendon reflexes, and hollow feet.

EXPRESSÃO TECIDUAL(Ubíquo)
Nervo tibial
5300.7 TPM
Cólon sigmoide
34.0 TPM
Esôfago - Junção
31.7 TPM
Esôfago - Muscular
30.5 TPM
Artéria coronária
19.6 TPM
OUTRAS DOENÇAS (9)
Roussy-Levy syndromeneuropathy, congenital hypomyelinating, 2Charcot-Marie-Tooth disease dominant intermediate DCharcot-Marie-Tooth disease type 2I
HGNC:7225UniProt:P25189
YARS1Tyrosine--tRNA ligase, cytoplasmicDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Tyrosine--tRNA ligase that catalyzes the attachment of tyrosine to tRNA(Tyr) in a two-step reaction: tyrosine is first activated by ATP to form Tyr-AMP and then transferred to the acceptor end of tRNA(Tyr) (Probable) (PubMed:25533949). Also acts as a positive regulator of poly-ADP-ribosylation in the nucleus, independently of its tyrosine--tRNA ligase activity (PubMed:25533949). Activity is switched upon resveratrol-binding: resveratrol strongly inhibits the tyrosine--tRNA ligase activity and pr

LOCALIZAÇÃO

CytoplasmNucleus

VIAS BIOLÓGICAS (1)
Cytosolic tRNA aminoacylation
MECANISMO DE DOENÇA

Charcot-Marie-Tooth disease, dominant intermediate C

A form of Charcot-Marie-Tooth disease, a disorder of the peripheral nervous system, characterized by progressive weakness and atrophy, initially of the peroneal muscles and later of the distal muscles of the arms. The dominant intermediate type C is characterized by clinical and pathologic features intermediate between demyelinating and axonal peripheral neuropathies, and motor median nerve conduction velocities ranging from 25 to 45 m/sec.

OUTRAS DOENÇAS (2)
neurologic, endocrine, and pancreatic disease, multisystem, infantile-onset 2Charcot-Marie-Tooth disease dominant intermediate C
HGNC:12840UniProt:P54577
GNB4Guanine nucleotide-binding protein subunit beta-4Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Guanine nucleotide-binding proteins (G proteins) are involved as a modulator or transducer in various transmembrane signaling systems. The beta and gamma chains are required for the GTPase activity, for replacement of GDP by GTP, and for G protein-effector interaction

LOCALIZAÇÃO

VIAS BIOLÓGICAS (10)
Extra-nuclear estrogen signalingGPER1 signalingThromboxane signalling through TP receptorADORA2B mediated anti-inflammatory cytokines productionProstacyclin signalling through prostacyclin receptor
MECANISMO DE DOENÇA

Charcot-Marie-Tooth disease, dominant intermediate F

A form of Charcot-Marie-Tooth disease, a disorder of the peripheral nervous system, characterized by progressive weakness and atrophy, initially of the peroneal muscles and later of the distal muscles of the arms. CMTDIF is characterized by onset around adolescence of slowly progressive distal muscle atrophy and weakness affecting the upper and lower limbs and resulting in steppage gait. There is distal sensory impairment with decreased reflexes. Nerve conduction velocities are variable, ranging from the demyelinating to the axonal range.

EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
43.9 TPM
Aorta
29.5 TPM
Skin Not Sun Exposed Suprapubic
27.7 TPM
Skin Sun Exposed Lower leg
26.6 TPM
Esôfago - Muscular
25.8 TPM
OUTRAS DOENÇAS (1)
Charcot-Marie-Tooth disease dominant intermediate F
HGNC:20731UniProt:Q9HAV0

Medicamentos aprovados (FDA)

1 medicamento encontrado nos registros da FDA americana.

💊 Jynarque (TOLVAPTAN)
Ver no DailyMed/FDA

Variantes genéticas (ClinVar)

387 variantes patogênicas registradas no ClinVar.

🧬 INF2: GRCh37/hg19 14q32.2-32.33(chr14:97521552-107285437)x3 ()
🧬 INF2: GRCh37/hg19 14q32.2-32.33(chr14:101180490-106329074)x1 ()
🧬 INF2: NM_022489.4(INF2):c.3706G>T (p.Asp1236Tyr) ()
🧬 INF2: NM_022489.4(INF2):c.604A>C (p.Asn202His) ()
🧬 INF2: NM_022489.4(INF2):c.529C>G (p.Arg177Gly) ()
Ver todas no ClinVar

Classificação de variantes (ClinVar)

Distribuição de 3 variantes classificadas pelo ClinVar.

1
2
Patogênica (33.3%)
VUS (66.7%)
VARIANTES MAIS SIGNIFICATIVAS
CLCN1: NM_000083.3(CLCN1):c.1437_1450del (p.Pro480fs) [Pathogenic/Likely pathogenic]
SH3TC2: NM_024577.4(SH3TC2):c.3292A>C (p.Thr1098Pro) [Uncertain significance]
IGHMBP2: NM_002180.3(IGHMBP2):c.1924T>C (p.Tyr642His) [Uncertain significance]

Vias biológicas (Reactome)

49 vias biológicas associadas aos genes desta condição.

Toll Like Receptor 4 (TLR4) Cascade Retrograde neurotrophin signalling Gap junction degradation Formation of annular gap junctions NOSTRIN mediated eNOS trafficking MHC class II antigen presentation Lysosome Vesicle Biogenesis Golgi Associated Vesicle Biogenesis Recycling pathway of L1 Clathrin-mediated endocytosis NGF-stimulated transcription Degradation of CDH1 trans-Golgi Network Vesicle Budding VxPx cargo-targeting to cilium COPI-mediated anterograde transport COPI-dependent Golgi-to-ER retrograde traffic Assembly and Release of Dengue Virus Virions Dengue Virus-Host Interactions EGR2 and SOX10-mediated initiation of Schwann cell myelination Cytosolic tRNA aminoacylation Activation of G protein gated Potassium channels Glucagon signaling in metabolic regulation G-protein activation Glucagon-like Peptide-1 (GLP1) regulates insulin secretion ADP signalling through P2Y purinoceptor 12 G beta:gamma signalling through PI3Kgamma Prostacyclin signalling through prostacyclin receptor Adrenaline,noradrenaline inhibits insulin secretion Ca2+ pathway G alpha (q) signalling events G alpha (12/13) signalling events G beta:gamma signalling through PLC beta G alpha (s) signalling events ADP signalling through P2Y purinoceptor 1 G alpha (i) signalling events G alpha (z) signalling events Glucagon-type ligand receptors Thromboxane signalling through TP receptor Vasopressin regulates renal water homeostasis via Aquaporins Thrombin signalling through proteinase activated receptors (PARs) Presynaptic function of Kainate receptors Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding G beta:gamma signalling through BTK G beta:gamma signalling through CDC42 Extra-nuclear estrogen signaling GPER1 signaling ADORA2B mediated anti-inflammatory cytokines production High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells Inhibition of voltage gated Ca2+ channels via Gbeta/gamma subunits

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Doença de Charcot-Marie-Tooth intermédia autossómicadominante

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

Pesquisa e ensaios clínicos

Nenhum ensaio clínico registrado para esta condição.

🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
3 papers (10 anos)
#1

[Analysis of a pedigree with autosomal dominant intermediate Charcot-Marie-Tooth disease type E and nephropathy].

Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics2019 Sep 10

To explore phenotypic and mutational characteristics of a pedigree affected with autosomal dominant Charcot-Marie-Tooth disease (CMT) and nephropathy. Clinical data of the proband and his family members was collected. Electrophysiology, renal biopsy and next-generation sequencing were carried out for the proband. The proband presented with distal lower limb weakness and proteinuria in childhood. His mother and brother had similar symptoms. Electrophysiological test of the proband revealed demyelination and axonal changes in both motor and sensory nerves. Renal biopsy suggested focal segmental glomerulosclerosis. Genetic testing revealed a heterozygous c.341G>A (p.G114D) mutation in exon 2 of the INF2 gene. The phenotypic feature of the pedigree is autosomal dominant intermediate CMT and focal segmental glomerulosclerosis, which may be attributed to the c.341G>A mutation of the INF2 gene.

#2

Novel GARS mutation presenting as autosomal dominant intermediate Charcot-Marie-Tooth disease.

Journal of the peripheral nervous system : JPNS2019 Mar

We report the first family with a glycyl-tRNA synthetase (GARS) mutation with autosomal dominant intermediate Charcot-Marie-Tooth disease (DI-CMT). The proband and the proband's father presented with gait disturbance and hand weakness. Both patients displayed moderately decreased conduction velocities (MNCV) (ranging from 29.2 to 37.8 m/s). A sural nerve biopsy of the father revealed evidence of both axonal loss and demyelination. On exome sequencing, in both the proband and his father, we identified a novel missense mutation (c.643G > C, p.Asp215His) in the GARS gene in a heterozygous state, which is considered to be pathogenic for this DI-CMT family. The present study broadens current knowledge about intermediate CMT and the phenotypic spectrum of defects associated with GARS.

#3

Novel GARS mutation presenting as autosomal dominant intermediate Charcot-Marie-Tooth disease: Intermediate or axonal?

Journal of the peripheral nervous system : JPNS2019 Mar

Publicações recentes

Ver todas no PubMed

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Doença de Charcot-Marie-Tooth intermédia autossómicadominante.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Doença de Charcot-Marie-Tooth intermédia autossómicadominante

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Ordenadas pelo número de sintomas em comum.

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. [Analysis of a pedigree with autosomal dominant intermediate Charcot-Marie-Tooth disease type E and nephropathy].
    Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics· 2019· PMID 31515790mais citado
  2. Novel GARS mutation presenting as autosomal dominant intermediate Charcot-Marie-Tooth disease.
    Journal of the peripheral nervous system : JPNS· 2019· PMID 30394614mais citado
  3. Novel GARS mutation presenting as autosomal dominant intermediate Charcot-Marie-Tooth disease: Intermediate or axonal?
    Journal of the peripheral nervous system : JPNS· 2019· PMID 30873681mais citado
  4. A novel INF2 mutation in a Korean family with autosomal dominant intermediate Charcot-Marie-Tooth disease and focal segmental glomerulosclerosis.
    J Peripher Nerv Syst· 2014· PMID 24750328recente

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:90114(Orphanet)
  2. MONDO:0019548(MONDO)
  3. GARD:12436(GARD (NIH))
  4. Variantes catalogadas(ClinVar)
  5. Busca completa no PubMed(PubMed)
  6. Q3281252(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Doença de Charcot-Marie-Tooth intermédia autossómicadominante
Compêndio · Raras BR

Doença de Charcot-Marie-Tooth intermédia autossómicadominante

ORPHA:90114 · MONDO:0019548
Prevalência
Unknown
Herança
Autosomal dominant
CID-11
Início
Adolescent, Adult, Childhood
Prevalência
0.0 (Worldwide)
MedGen
UMLS
C5680178
EuropePMC
Wikidata
Papers 10a
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades